STAA · STAAR Surgical Company
$22.61
+0.53% last session
End-of-day data · close of 2026-10-23
Market cap
$1B
Enterprise value
$1B
Trailing P/E
282.6
Forward P/E
20.3
Dividend yield
0.0%
Beta
1.18
Avg volume
1M
Employees
1K
Daily Change %
0.53%
5 Days Change
3.34%
10 Days Change
3.53%
30 Days Change
18.50%
60 Days Change
-2.46%
Month to Day Change
1.03%
Year to Day Change
-2.08%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — STAA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-29
Latest call per bank · past 12 months
Jefferies
Buy$23.00
+1.7% vs priceUBS
Sell$19.00
-16.0% vs priceWells Fargo
Equal-Weight$25.00
+10.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-29 | Stifel | Upgrade | Hold → Buy | $28.00 → $31.00 |
| 2026-09-22 | Jefferies | Maintains | Buy | $28.00 → $23.00 |
| 2026-08-17 | Stifel | Maintains | Hold | $31.00 → $28.00 |
| 2026-08-13 | UBS | Maintains | Sell | $20.00 → $19.00 |
| 2026-08-13 | Jefferies | Maintains | Buy | $29.00 → $28.00 |
| 2026-08-13 | Wedbush | Maintains | Outperform | $40.00 → $37.00 |
| 2026-08-04 | Wedbush | Reiterates | Outperform | $40.00 |
| 2026-07-28 | UBS | Initiates | Sell | $0.00 → $20.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 54 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 0.8% above the 50-day MA ($22.43).
- bearish: Price vs 200-day MA: Trading 4.0% below the 200-day MA ($23.54).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.12) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($16.10) and high ($33.34).
STAA Price Chart
Loading chart for STAA…
Fundamentals
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
More in Medical Instruments & Supplies
ISRG
Intuitive Surgical, Inc.
$160B -21.6% YTD
BDX
Becton, Dickinson and Company
$54B 33.9% YTD
MDLN
Medline Inc.
$46B -17.0% YTD
RMD
ResMed Inc.
$36B 5.9% YTD
ALC
Alcon Inc.
$34B -9.9% YTD
WST
West Pharmaceutical Services, I
$28B 43.5% YTD
SOLV
Solventum Corporation
$15B 10.4% YTD
BAX
Baxter International Inc.
$13B 34.4% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.